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RESEARCH ARTICLE
Efficacy and Safety of Topiramate as the First - Line Drug
 in the Treatment of Infantile Spasms 
Abstract
Objective
Infantile Spasms (IS) is one of the catastrophic epileptic syndromes of infancy. 
The purpose of this study was to evaluate clinical efficacy and safety of 
topiramate (TPM) as the first -line drug in the treatment of infantile spasms.
Materials and Methods
In a quasi- experimental study, efficacy and safety of TPM in treatment of forty 
children with IS who were referred to pediatric neurology clinic of Shahid 
Sadoughi University of Medical Sciences in Yazd, Iran, from September 2008 
to 2010 was evaluated. 
Results
Twenty two girls (55%) and 18 boys (45%) with a mean age of 9.2 ± 3.9 months 
(range= 3-20 months) were evaluated. Ninety percent of the patients had 
symptomatic IS. At the end of three months of TPM treatment, 40% of the 
patients became seizure free, 27.5% had more than 50% reduction in seizure 
frequency, 27.5% had no notable change in seizure frequency and 5% had an 
increased frequency of seizures.
Transient and mild side effects, which were seen in 32.5% of the patients, 
included drowsiness in 15%, hypotonia and hyperthermia (each one) in 7.5% 
and anorexia and weight loss in 2.5%. All side effects disappeared in two or 
three weeks of treatment. 
Conclusion
Topiramate is an effective and safe drug in the treatment of IS and could be 
considered as the first line of treatment. 
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Introduction
Infantile Spasms (IS) is the most common myoclonic epilepsy of infancy (1). The 
incidence of IS varies between 0.2 - 0.6 per 100 with a peak between 3 to 7 months 
of age. In 93% of the cases, it occurs before the age of two (2). The spasms are 
bilateral, symmetric sudden contractions of neck, trunk and extremities, and may be 
flexor, extensor or mixed type. The spasms may be single, but often occur in clusters 
with 20 to 100 spasms in a single cluster. Clusters frequently occur while patients 
are drowsy or immediately on wakening from sleep (1, 2). 
A hypsarrhythmia pattern is noted on electroencephalography of these patients, 
which consists of chaotic, bilaterally asynchronous high-voltage polyspike and slow 
wave discharges interspersed with multifocal spikes and slow waves (3). 
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Etiologic classification of IS includes
1.Symptomatic: with identifiable prenatal, perinatal, and 
postnatal causes with developmental delay at the time of 
presentation 
2.Cryptogenic: an unknown underlying cause, 
normal development at the onset of the spasms, 
normal neurological exams and neuroimaging and no 
abnormalities in metabolic evaluations 
3.Idiopathic: pure functional cerebral dysfunction with 
complete recovery, no residual dysfunction, normal 
neurodevelopment, normal neuroimaging and normal 
etiologic evaluations. This class is based on final 
outcome, and cannot be confirmed with certainty based 
on the history and presenting symptoms. The terms 
idiopathic and cryptogenic have been used as synonyms 
in many studies (2, 4,5,6). 
Treatment should be started without delay since 
early control of spasms may improve prognosis 
and is accompanied by a higher chance for normal 
develpomental outcome (5- 7). 
There is no consensus on the first choice of drug 
treatment of IS and no single treatment regimen 
could be considered superior to others. ACTH or oral 
corticosteroids, vigabatrin and other drugs such as 
valproic acid, nitrazepam, pyridoxine, topiramate, 
zonisamide, lamotrigine, levetiracetam, felbamate, 
ganaxolone, liposteroid, thyrotropin-releasing hormone, 
intravenous immunoglobulin and also the ketogenic diet 
may be used for the treatment of spasms as the first or 
second line drugs (2,7,8).
ACTH is expensive and difficult to obtain in many 
countries and cities (including Yazd), and side effects 
of ACTH and oral corticosteroids include hypertension, 
infection, electrolyte abnormalities, weight changes, 
hyperglycemia, hypertrophic cardiomyopathy, 
adrenocortical dysfunction,  sleep disturbance, brain 
shrinkage, sleep and behavior abnormalities, subdural 
hematoma / effusion, cushingoid appearance, deve-
lopment of new seizure types, decreased bone 
density sometimes with fractures, skin rashes with 
intravascular coagulation and even death (2,7,9).
Irreversible visual field defect is seen in 30 - 50 % of the 
children treated with vigabatrin (10).
It is difficult to provide recommendations for the 
treatment of IS in the absence of comparative trials. New 
antiepileptic drugs with better efficacy and fewer side 
effects are fiercely needed.
Topiramate (TPM) is one such agent and can also be 
used as a second-line agent for IS of tuberous sclerosis, 
and as a first-line agent for other symptomatic IS. 
Its anticonvulsant effect is based on the following 
mechanisms: 
a) blockade of the voltage-dependent Na channels 
b) enhancement of the inhibitory activity of GABA  
c) inhibition of excitatory neurotransmission by blocking 
Kainate/AMP glutamate receptors
 d) inhibition of erythrocyte carbonic anhydrase (2,7,11-
20).
TPM may induce metabolic acidosis, especially in 
patients with renal disease or in those on a ketogenic diet 
or zonisamide (11). 
There is no consensus on mean daily dose of TPM (12) 
and up to 35 mg/kg per day has been used in IS (7,12,13, 
19), but a maximum dose of 12 mg/kg/day is effective 
and safe (16,17,21). Slow titration of drug dose has 
improved the efficacy and safety of TPM in the treatment 
of intractable epilepsy seizures (21).
The purpose of this study was to evaluate clinical efficacy 
and safety of TPM as the first -line drug in controlling 
infantile spasms in Yazd- Iran. 
Materials and Methods 
This quasi- experimental (before and after) study 
was conducted on children with infantile spasms who 
referred to the pediatric neurology clinic of Shahid 
Sadoughi University of Medical Sciences, Yazd, Iran, 
from September 2008 to 2010. 
The sample size, based on Z formula and a confidence 
interval of 95% with 80% power, S= 30 and d=15 to 
detect a significant difference between the two groups 
with a level of 0.05, was assessed to be 40 persons.
The diagnostic criteria for the IS in this study were 
based on International League Against Epilepsy (ILAE) 
classification and done with two groups: symptomatic or 
cryptogenic, and the main clinical criteria were spasms 
that usually occurred in clusters, almost always occurred 
during the first two years of life and frequently occurred 
in a drowsy state (4).
Care was taken to include IS patients aged 2 months to 2 
years who did not use any antiepileptic drugs, ACTH or 
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oral corticosteroids, and did not have metabolic acidosis 
or kidney dysfunction.
Video –EEG monitoring facilities were not available in 
our city and successful management of IS was shown as 
the cessation of clinical seizures.
Variables such age, sex, age of seizure onset, type and 
frequency of spasms (flexor, extensor or mixed based on 
history), etiologic classification, EEG and neuroimaging 
results were reviewed. 
Topiramate started as a minimum of two divided doses 
and to minimize side effects of the drug, the dose 
increased in a weekly fashion to reach the maximum 
dose or the dose which controlled seizures in a four-
week period as follows: 3, 6, 9, 12 mg/kg/day.
Laboratory blood analysis consisted of calcium, 
urea, creatinine, alanine aminotransferase, aspartate 
aminotransferase and complete blood count. EEG was 
also done at the beginning of the study and after three 
months of treatment. 
Patients were visited for three consecutive months and 
clinical information of their parents regarding the type 
and number of spasms, side effects of the drug and 
paraclinical investigations was recorded. At the end 
of the period, drug efficacy and safety was evaluated. 
Clusters frequency in a week was compared to that of 
before and three months after drug use and the following 
classification was done on this basis: 
1. Seizure free: all the spasms stopped
2. Improved: more than 50 % reduction in spasms 
frequency
3. Unchanged: no notable change was noted in spasms 
frequency
4. Worsened: spasms frequency increased by more than 
25%
Cessation of all spasms or more than 50% reduction in 
seizure frequency was considered as a good response. 
Data was analyzed using SPSS 15 statistical software. 
Chi-square test or Fisher exact test were used for data 
analysis of qualitative variables and mean values were 
compared using paired -samples t-test. Differences were 
considered significant at P values of less than 0.05.
An informed consent was signed by patients’ parents and 
the study protocol was approved by the ethics committee 
of Shahid Sadoughi University of Medical Sciences, 
Yazd, Iran. The researchers received no support from the 
drug company.  
Results
Topiramate efficacy was evaluated in 40 infantile spasms 
patients. Clinical characteristics of patients are presented 
in Table I.
Etiology in symptomatic IS group was inborn error 
of metabolism in 10, structural CNS dysgenesia in 
7, hypoxic ischemic encephalopathy in 6, congenital 
infection in 5, tuberous sclerosis in 2 and chromosomal 
abnormality and genetic syndromes in 6 children. 
Abnormal neuroimaging results were brain atrophy 
in 15 patients (37.5%), intracranial calcification in 5 
(12.5%), structural CNS dysgenesia in 5 (12.5%) and 
hydrocephaly in one (2.5%) patient.
EEG showed hypsarrhythmia in 33 (82.5 %) children.
Results of efficacy analysis of TPM therapy at the end of 
three months are shown in Table II and a good response 
(all seizures stopped or more than 50% reduction in 
seizure frequency) was seen in 67.5% of the patients.
Mean seizure frequency/week, before and after treatment, 
was 32.4 ±16.5 (range: 1-105) and 13.08 ±10.5 (range: 
0- 55) respectively, demonstrating the efficacy of TPM 
(Confidence interval: 95%, t=4.34, P.value = 0.0001) 
The mean dose of TPM for seizure control was 6.9 ± 3.4 
mg/kg/day (range: 3-12). 
Results of efficacy analysis based on etiologic class, 
type of infantile spasms, electroencephalography and 
neuroimaging results are illustrated in Table III indicating 
that topiramate efficacy was not statistically different in 
these clinical and paraclinical characteristics of patients. 
No serious paraclinical adverse events such as 
hematologic abnormality, hepatotoxicity and 
nephrotoxicity were seen in two groups.
Transient and mild side effects which were seen in 
32.5% (N=13) of the patients consisted of drowsiness 
in 15% (N=6), hypotonia and hyperthermia (each) in 
7.5% (N=3) and anorexia and weight loss in 2.5% (N= 
1). All side effects disappeared in one or two weeks and 
no patient stopped treatment. 
Discussion
In this study, 90% of the participants had symptomatic 
IS among whom, inborn error of metabolism was the 
most common cause. In a study in Thailand, 45.8% 
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were symptomatic and the most common etiology in 
symptomatic cases was hypoxic ischemic encephalopathy 
(22). In karvelas’s study, 63% were symptomatic IS 
and cortical dysgenesia was the most frequent cause. 
(23) In a study in Taiwan, 80% of the patients were 
symptomatic and tuberous sclerosis, asphyxia, and 
CNS malformation were the most common causes (24); 
in another study, 70% were symptomatic and brain 
malformations and tuberous sclerosis were seen in 
35% of them. (25) In Zagreb, 81.2% had symptomatic 
IS and hypoxic-ischemic encephalopathy was the most 
common etiologic factor (26). In a study by Peltzer et al., 
84% were symptomatic (13). 
In the present study, 82.5% of the patients had a 
hypsarrhythmic pattern in EEG. Based on pediatric 
neurology textbooks, hypsarrhythmia may be seen in 
66% of the patients and is most obvious in non-rapid 
eye movement (REM) sleep (3). This EEG pattern 
appears after 3-4 months of age and may only be present 
periodically. It may change or even resolve with time 
and during REM sleep and immediately after arousal 
from REM or non-REM sleep, electroencephalography 
can be normal for up to several minutes (2,3).
In this study, good response to drugs was not different in 
symptomatic and cryptogenic IS which dose not agree to 
other studies (6, 7,13,27).
In our study, control of all spasms was seen in 40 % 
of patients. However, in other studies this rate varied 
between 16.7 % and 57.4 % (12, 13, 15 - 19, 23,27, 28). 
In the present study, more than 50% reduction in seizure 
frequency was seen in 27.5 % of the children. this rate 
was 33% (18), 36% (19), 47% (16) and 85% (29) in other 
studies. In a study in Valencia, 75% of IS patients (three 
of four) showed more than 75% reduction in spasms.
(30) In Watemberg study, 87.5% of IS (seven of eight) 
cases improved with TPM treatment (31). 
A possible explanation for these discrepancies is 
difference in sample size, duration of treatment, selection 
method of patients and dosage of drug.
Dose of TPM in this study was 3- 12 mg/kg/day while it 
was 25 mg/kg/day (19), 3.57-20 mg/kg/day (15) 1.56-26 
mg/kg/day (28), 1-12 mg/kg/day (17), 3 -27 mg/kg/day 
(18) and 1-10 mg/kg/day (32) in other studies.
In our study, mean dose of TPM for seizure control was 
6.9 ± 3.4 mg/kg/day which was almost similar to Taiwan 
study (7.35 ± 4.9 mg/kg/day on 13 children) (29).
In this study, TPM adverse effects were seen in 32% of 
the children and lethargy was the most common side 
effect.
 In a study by Mikaeloff et al, the most common adverse 
effects were neurobehavioral problems (drowsiness, 
fatigue, hyperactivity) and gastrointestinal disorders 
(anorexia, loss of appetite) (12). About 10.5% of the 
patients (2 of 19) in a study by Pletzer et al showed side 
effects such as appetite loss, tremors, and lethargy (13). 
 Zou et al conducted two studies in china; in one study, 
38.8% had adverse effect with anorexia and somnolence 
being the most common (15) and in the other one, 26% 
had side effects including poor appetite and anorexia, 
absence of sweating, and sleeplessness (28).
 In a study by Korinthenberg et al in Germany, adverse 
effects were seen in 25% of the patients with sedation, 
loss of appetite, weight loss, and metabolic acidosis 
being the most common (16). 
In Hosain’s study, irritability was the most common 
side effect (18). Two studies were conducted by Grosso; 
in one study, adverse effects were seen in 58% of the 
children including weight loss, hyperthermia, sedation, 
and nervousness but the majority of them disappeared 
after slow titration or decreasing drug dose (33) and 
in the other one, the most common side effects were 
drowsiness, irritability, hyperthermia, and anorexia (27). 
In a study by Al Ajlouni in Amman, Mild to moderate 
adverse effects, mainly somnolence, anorexia and 
nervousness were seen in 25 (53%) children. Only one 
child developed hypothyroidism.(32) Fifteen percent of 
the patients (2 of 13) in Valencia’s study developed side 
effects, mainly lethargy, hyperthermia, and anorexia (30) 
In conclusion, Education of parents and children’s 
health care providers for early referral, diagnosis and 
treatment of infantile spasms is necessary. Topiramate 
is an effective and safe drug for the treatment of IS and 
should be considered as the first line of treatment.
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